Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
Comparison of clinical trial major and clinically relevant nonmajor... | Download Table
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation - Medical Conferences
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH - Kaatz - 2015 -
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH - Kaatz - 2015 -
Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF | Journal of the American Heart Association
Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis - Nikhil Nair Hariharan, Kashyap Patel, Omaike Sikder, Kanjana S
Practical Management of Anticoagulation in Patients With Atrial Fibrillation | Journal of the American College of Cardiology
JCM | Free Full-Text | Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
new oral anticoagulants | PPT
Nephrology Journal Club on X: "T1h: Outcomes were defined accordingly with International Society on Thrombosis and Haemostasis @isth #NephJC https://t.co/b0tQMjYKbE" / X
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor - ScienceDirect
Direct Oral Anticoagulants: A User's Guide | Consultant360
Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials | Scientific Reports
Long-Term Risk of Clinically Relevant Non-Major Bleeding During Extended Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis - ISTH Congress Abstracts
PPT - John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA Lars Wallentin, MD, PhD Uppsala Clinical R PowerPoint Presentation - ID:154927
Clinically relevant non-major bleeding and intra-cranial haemorrhage in... | Download Scientific Diagram
CRNM - "Clinically Relevant Non-Major Bleeding" by AcronymsAndSlang.com
Were Major Bleeds Defined in the Same Way - Novel Oral Anticoagulants - Recent Advances in Oral Anticoagulation Therapy for Patients with Atrial Fibrillation
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
Assessing Bleed Severity and Managing Major and Non-Major Bleeds | Download Scientific Diagram
Abstract 12434: Long-Term Clinical Outcomes After Major versus Minor Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry | Circulation
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer | CMAJ
